Jin-Ji Yang

Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute

China

SCHOLARLY PAPERS

4

DOWNLOADS

98

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (4)

1.

A Phase 1b Study of Savolitinib Plus Gefitinib for Patients with EGFR-Mutated MET-Amplified Advanced Non-Small-Cell Lung Cancer

Number of pages: 40 Posted: 20 Jan 2020
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Beijing Cancer Hospital, Nanjing Medical University - Department of Oncology, Fudan University, Harbin Medical University - Cancer Hospital, Guangzhou Medical University - First Affiliated Hospital, Jilin University (JLU) - First Affiliated Hospital, Government of the People's Republic of China - 307th Hospital, Central South University - Hunan Cancer Hospital, Tongji University - Shanghai Pulmonary Hospital, Soochow University - First Affiliated Hospital, AstraZeneca Pharmaceuticals - United States, AstraZeneca Pharmaceuticals - United States, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - China and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 38 (548,478)

Abstract:

Loading...

Savolitinib; Gefitinib; EGFR-TKI; NSCLC; China; MET

2.

The Resistance Landscape of Abivertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, and Clinical Strategy to Overcome Resistance in EGFR T790M-Positive Non-Small Cell Lung Cancer

Number of pages: 37 Posted: 28 Jan 2019
Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences, Burning Rock Biotech, Burning Rock Biotech, Burning Rock Biotech, Burning Rock Biotech, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences, ACEA Therapeutics Inc., ACEA Therapeutics Inc., ACEA Therapeutics Inc., Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 36 (558,925)

Abstract:

Loading...

Abivertinib, resistance, EGFR amplification

3.

Genomic Signature for Personalized Adjuvant Therapy in Resected EGFR-Mutant Stage II-III Non-Small Cell Lung Cancer: Results from Phase 3 ADJVANT/CTONG1104 Study

Number of pages: 30 Posted: 28 Oct 2020
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Geneseeq Technology Inc. - Nanjing Geneseeq Technology Inc., Fudan University - Zhongshan Hospital, Zhejiang Cancer Hospital, Geneseeq Technology Inc. - Nanjing Geneseeq Technology Inc., Geneseeq Technology Inc. - Nanjing Geneseeq Technology Inc., Central South University - Hunan Cancer Hospital, Fujian Medical University - Union Hospital, Jilin Provincial Cancer Hospital, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Geneseeq Technology Inc. - Nanjing Geneseeq Technology Inc., Geneseeq Technology Inc. - Geneseeq Research Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 15 (695,744)

Abstract:

Loading...

Adjuvant therapy, EGFR, TKI, chemotherapy, non-small cell lung cancer

4.

Genomic Stability and Non-Exhausted Immune Phenotype in Indolent T4N0M0 (Diameter ≥7 cm) Non-Small Cell Lung Cancers

Number of pages: 33 Posted: 15 Sep 2021
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Southern Medical University - Second School of Clinical Medicine, Geneplus-Beijing Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Geneplus-Beijing Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Geneplus-Beijing Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Geneplus-Beijing Institute, Geneplus-Beijing Co. Ltd., Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 9 (743,359)

Abstract:

Loading...

intra-tumoural heterogeneity, clonal structure, chromosomal instability, indolent tumour, non-small cell lung cancer